ZURICH, Switzerland--(BUSINESS WIRE)--

Myriad Genetics GmbH announced today that a presentation entitled Current Variant of Uncertain Significance Rates in BRCA 1/2 and Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) Testing, was presented today at the European Human Genetics Conference in Nurnberg, Germany. The study highlights Myriads best-in-class variant classification process and variant of uncertain significance rate.

Researchers analyzed the variant of uncertain significance rate for the BRACAnalysis test (BRCA 1 and BRCA 2 genes) test as well as the COLARIS test (MLH1, MSH2, MSH6, PMS2 and EPCAM genes). From 2002 to 2012, Myriads overall uncertain variant rate decreased due to significant investments made in the development and application of improved processes and statistical techniques and the implementation of a targeted program designed to gather data on family members. Across all ancestries, the BRCA 1 and BRCA 2 variant of uncertain significance rate declined from 12.8% to 2.9%. Further, the variant of uncertain significance rate for Lynch syndrome, a test analyzing the MLH1, MSH2, MSH6, and EPCAM genes, declined to 6.6% in 2012. The variant of uncertain significance for PMS2 gene test, also for Lynch Syndrome, was 4.0%.

This data underscores the importance of a world-class variant classification program as well as the high level of accuracy and sensitivity of Myriads genetic tests. Further, through the investment in research and development for its existing tests, the Company has deepened its understanding of variants and variant classification. Myriad continues to invest furthering this knowledge base in an effort to provide best-in-class testing to patients globally.

Current tests available in Europe have a very high variant of uncertain significance rate, often 25 to 30 percent, stated Gary King, Executive Vice President of International Operations at Myriad. We are pleased to bring Myriads technology and variant classification program to Europe, to enhance the quality of genetic testing available to patients and physicians.

About Myriad Genetics GmbH

Myriad Genetics GmbH is the international headquarters of Myriad Genetics, Inc., a global molecular diagnostic company. The Company is dedicated to making a difference in patients lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of nine molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a focus on improving an individual's decision making process for monitoring and treating disease. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Companys variant classification program; and the Companys strategic directives under the caption About Myriad Genetics. These forward-looking statements are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and companion diagnostic services may decline or will not continue to increase at historical rates; the risk that we may be unable to expand into new markets outside of the United States; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and companion diagnostic services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and companion diagnostic services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and companion diagnostic services and any future products are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with manufacturing our products or operating our laboratory testing facilities; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of healthcare payment systems; risks related to our ability to obtain new corporate collaborations and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we acquire; the development of competing tests and services; the risk that we or our licensors may be unable to protect the proprietary technologies underlying our tests; the risk of patent-infringement and invalidity claims or challenges of our patents; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading Risk Factors contained in Item 1A in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Continue reading here:

Myriad Presents Variant of Uncertain Significance Rates at European Human Genetics Conference 2012